Form 4: Disc Medicine CEO John Quisel Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Disc Medicine's CEO, John Quisel, exercised stock options and sold shares of common stock on December 23, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On December 23, 2024, John Quisel, CEO of Disc Medicine, Inc., executed a stock option to purchase 19,820 shares of common stock at a price of $2.65 per share.
- Simultaneously, Quisel sold a total of 19,820 shares of Disc Medicine common stock in multiple transactions at weighted average prices of $62.3777, $63.1185, and $63.8017.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on July 2, 2024.
- Following these transactions, Quisel directly owns 72,065 shares of Disc Medicine common stock and holds options for 41,830 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports routine transactions under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The market will likely interpret this as a standard part of executive compensation and portfolio management.
Comparison to Industry Standards
- Executive compensation packages in the biotech industry often include stock options and restricted stock units.
- Rule 10b5-1 trading plans are a common tool used by executives at companies like Amgen, Gilead, and Biogen to manage their stock holdings and comply with insider trading regulations.
- The size of the transaction is relatively small compared to the overall market capitalization of Disc Medicine, suggesting it's unlikely to have a significant long-term impact on the stock price.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
- The transactions are unlikely to significantly affect employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2024-07-02 | Date of adoption of Rule 10b5-1 trading plan. |
| 2024-12-23 | Date of stock option exercise and share sales. |
| 2024-12-26 | Date of signature on the Form 4 filing. |
| 2030-10-22 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.